Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509344 | 1.00 | USP2 (0.64) | USP2KDM4EALDH1A1ANPEPL3MBTL1 | |
| SCHEMBL4493204 | 1.00 | USP2 (0.64) | USP2KDM4EALDH1A1ANPEPL3MBTL1 | |
| SCHEMBL6319425 | 0.82 | MEN1 (0.58) | USP2KDM4EANPEPL3MBTL1TSHR | |
| SCHEMBL403305 | 0.81 | USP2 (0.64) | USP2KDM4EALDH1A1ANPEPL3MBTL1 | |
| SCHEMBL14168302 | 0.81 | USP2 (0.58) | USP2KDM4EALDH1A1ANPEPL3MBTL1 | |
| SCHEMBL709506 | 0.80 | USP2 (1.00) | USP2KDM4EALDH1A1ANPEPL3MBTL1 | |
| SCHEMBL4489543 | 0.77 | USP2 (0.57) | USP2KDM4EALDH1A1ANPEPL3MBTL1 | |
| SCHEMBL4150403 | 0.77 | USP2 (0.57) | USP2KDM4EALDH1A1ANPEPL3MBTL1 | |
| Oxalic Acid SCHEMBL28812698 | 0.76 | USP2 (0.62) | USP2KDM4EALDH1A1ANPEPL3MBTL1 | |
| SCHEMBL2780188 | 0.76 | USP2 (0.75) | USP2KDM4EALDH1A1ANPEPL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6653308-B2 | Anticancer agents; antidiabetic agents; antiinflammatory agents | SUGEN, INC. | 2003-11-25 | — | — | US | claimed |
| US-7582756-B2 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors | SUGEN, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | SUGEN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-7179910-B2 | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | SUGEN, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045709-A1 | 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP4K2, MAP4K3, CDK2 | USP2 2330/4885KDM4E 884/4885ALDH1A1 3371/4885 |
| US-20070027149-A1 | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors | PDPK1, MAP4K2, MAP4K3 | USP2 2777/4885KDM4E 1154/4885ALDH1A1 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.